AI-native pharma company, bringing new treatments to patients faster and more efficiently.
New York, NY
- Tweets 225
- Following 30
- Followers 2,370
- Likes 107
Pinned Tweet
The world has more promising discovered drug candidates than ever. The problem is developing them. We built Formation Bio to fix that, using AI to develop drugs faster and with a higher likelihood of success.
Thank you @amyfeldman and @Forbes telling the story of our mission, and our vision for the future of pharma.
forbes.com/sites/amyfeldman/…
3
8
59
39,733
Formation Bio made #7 on @FastCompany's Best Workplaces for Innovators 2026.
This piece highlights one of our internal systems: ARK (AI-ready Repository of Knowledge), our in-house AI platform that connects all internal systems and data across the company. Full write-up here: fastcompany.com/91591991/for…
Our open roles: formation.bio/careers
Learn more about ARK: formation.bio/blog/ark-mcp-g…
1
1
2
133
Proud to be selected as #7 on @FastCompany's 2026 100 Best Workplaces for Innovators, plus as a winner on the Biotech, Healthcare & Life Sciences list.
Find us on the full list: fastcompany.com/best-workpla…
We're hiring across New York and Boston now: formation.bio/careers
1
163
Our CEO @BenjamineYLiu recently sat down with @LanceGlinn on @NYSE's Inside the ICE House to talk about how and why Formation Bio is tackling the drug development bottleneck, a problem that is only set to grow as the number of drugs at the top of the funnel increases. Links to listen in comments:
Hear from @formationbio co-founder & CEO Ben Liu on @ICEHousePodcast where he talks about...
- Bottleneck's slowing down drug development
- AI's impact on drug discovery
- Bringing new medicines to patients
Spotify: open.spotify.com/episode/60l…
YouTube: piped.video/DaN84yEwBvU?si=tOHz…
1
4
292
Spotify: open.spotify.com/episode/60l…
Youtube: piped.video/watch?v=DaN84yEw…
1
82
"In a world of drug discovery abundance, the scarce capability is no longer making drugs, but rather, knowing which drugs are worth developing."
@BenjamineYLiu, co-founder and CEO of Formation Bio, explains how AI will transform the economics of the pharma industry - link in replies
2
5
8
4,380
What drew Mike Ehlers, our new Chief Scientific Officer and Head of R&D, to Formation Bio? Hear it in his own words.
More on Mike’s life outside the lab in today’s @statnews executive moves column: statnews.com/pharmalot/2026/…
3
5
509
In his latest blog, our Principal Engineer Kenny Peng revisits the Unix philosophy (do one thing well, compose freely, shared interfaces) as a blueprint for agentic system design.
Using biopharma as the test case, he breaks down why hardcoded pipelines break down over time, and what composable alternatives require. Read here: linkedin.com/posts/kpeng_the…
2
217
Formation Bio retweeted
.@BenjamineYLiu has raised more than $600M for his AI-native biopharma company - and he's hiring!
@formationbio is applying AI to drug development, with a mission to bring new treatments to patients faster and more efficiently.
The team is hiring across the board, including:
- Director, Brand & Communications
- Senior Director or VP, Product
- General Manager (Drug Asset Lead)
- Principal Data Scientist, Medical Imaging
- Data Scientist, Portfolio Optimization
- Director, Business Development - Search & Evaluation
Full story + list of open roles in thread!
8
4
58
38,792
Formation Bio said it has appointed former Biogen research head Michael Ehlers as its chief scientific officer, bringing a seasoned drug and biotech veteran into the AI-focused health startup. bloomberg.com/news/articles/…
6
6
19
36,394
Formation Bio retweeted
Excited to share that Mike Ehlers is joining @formationbio as Chief Scientific Officer and Head of R&D. Over the course of his career as a scientist, drug developer, and investor, Mike has advanced 40+ drugs into the clinic, with approvals spanning Alzheimer's, ALS, MS, hemophilia, and SMA. Welcome to the team, Mike!
5
6
66
43,743
The @decodingbio AI x Bio Summit lands in NYC this week, and our CEO and Co-Founder @BenjamineYLiu will be speaking at the @awscloud Executive Reception that follows, joining a panel on what it takes to scale AI in pharma.
Read more and request to join: luma.com/iylrgtia
2
4
623
This Thursday, our Co-Founder & CEO @BenYLiu takes the stage at @decodingbio's AI x Bio Summit at the @NYSE to discuss how platform companies are creating new business models in biotech – alongside voices from @Nabla Bio, @Manifold Bio, and @Dimension Capital. Link to register: events.decodingbio.com/summi…
1
4
478
Formation Bio is now part of the @illumina Billion Cell Atlas, using the world's largest genome-wide perturbation dataset to sharpen how we choose assets, indications, and trial designs. Read more below.
The future of drug discovery is here. @formationbio is joining our Billion Cell Atlas program to help redefine what’s possible in AI-driven drug development, advancing the next generation of therapeutics.
By addressing key bottlenecks across the drug discovery continuum, the Atlas can help accelerate the journey from biological insights to approved drugs — bringing greater precision to how we understand what works, why it works, and which patient populations are most likely to benefit.
Together, we’re helping bring more precision medicines to life and reimagine what’s possible in biology.
Discover the next era: illumina.com/company/news-ce…
3
6
591
Our Co-Founder & CEO @BenjamineYLiu recently joined The Heart of Healthcare Podcast, @hoh_pod, to talk AI-native pharma, the development bottleneck, and getting more treatments to patients. Full episode here: piped.video/watch?v=6ZW1TTst…
1
1
7
8,060
Drug mechanisms with genetic support have a 2 to 3-fold higher probability of clinical success in clinical development compared to those without. We built an automated pipeline capable of transforming basic asset details into a structured genetic insights report in minutes, allowing our BD team to generate genetic insights for an entire quarterly pipeline in the time it once took to evaluate a handful of candidates.
2
3
384
The report for Asset X reveals two themes:
The first is encouraging: individuals carrying variants that mimic the drug’s effect show lower risk of several disease categories, including kidney and renal diseases (renal failure: β = -2.03; chronic kidney disease: β = -1.62) and degenerative joint conditions (arthrosis: β = -1.09 to -1.74). While no direct Crohn's disease signal was observed, the asset-specific analysis suggests IL-18 antagonism may increase liver disease risk (β = 2.41 to 3.85) — relevant given IBD-liver comorbidity.
The second is cautionary: the same variants are associated with increased risk for conditions including kidney stones (calculus of kidney: β = 3.54 to 3.70), liver disease (chronic hepatitis: β = 3.83 to 3.85), and certain malignancies. These associations flag potential adverse effects to monitor in clinical development.
1
97
Producing this output manually would take hours; the pipeline generates it in minutes. Human input totals roughly ten minutes across two checkpoints, preserving scientific judgment for where it matters most. Full blog on how we built the pipeline and how we’re continuing to develop it: formation.bio/blog/scaling-t…
87